During the past decade, Iu Eye at Carmel conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 1 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Iu Eye at Carmel" #1 collaborator was "Allergan" with 1 trials as a collaborator and "Optonol" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Iu Eye at Carmel" are "Cataract" (3 trials) and "Glaucoma" (3 trials). Many other conditions were trialed in "Iu Eye at Carmel" in a lesser frequency.

Most popular intervention types in "Iu Eye at Carmel" are "Drug" (4 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "5-fluorouracil" (1 trials), "Bimatoprost 0.03%" (1 trials), "Brimonidine Purite" (1 trials), "EconoPred Plus" (1 trials) and "Ex-Press mini shunt with mitomycin c" (1 trials). Other intervention names were less common.

The vast majority of trials in "Iu Eye at Carmel" are 5 trials for "All" genders.

Currently, there are NaN active trials in "Iu Eye at Carmel". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Iu Eye at Carmel, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Iu Eye at Carmel, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 1 trials that are defined as “Not Applicable".